New rabies vaccine shows promise in large trial

NCT ID NCT04127786

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This Phase 3 trial tested a new rabies vaccine (VRVg-2) in 1708 healthy children and adults in Thailand. The goal was to see if it works as well as two existing rabies vaccines when given before exposure to the virus. Participants received a series of shots, and some got a booster dose later. The study is complete, and results will show if the new vaccine is a safe and effective option.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Purified vero rabies vaccine - serum free (VRVg-2)
What this could lead to
If successful, this could provide a safe and effective alternative rabies vaccine for pre-exposure prevention in both children and adults.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The new vaccine must prove it is as good as existing ones, and rare side effects may still emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Investigational Site Number : 7640001

    Bangkok, 10330, Thailand

  • Investigational Site Number : 7640002

    Khon Kaen, 40002, Thailand

  • Investigational Site Number : 7640003

    Bangkok, 10700, Thailand

  • Investigational Site Number : 7640004

    Bangkok, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.